HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties

Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy

(2018) Shouheng Lin et al.   mAbs

Development of a robust reporter gene assay to measure the bioactivity of anti-PD-1/anti-PD-L1 therapeutic antibodies

(2017) Lan Wang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

(2017) Elena Burova et al.   MOLECULAR CANCER THERAPEUTICS

Phase I Pharmacokinetic Study of Nivolumab in Korean Patients with Advanced Solid Tumors

(2017) Keun‐Wook Lee et al.   ONCOLOGIST

Experimental animal modeling for immuno-oncology

(2017) Qi-Xiang Li et al.   PHARMACOLOGY & THERAPEUTICS

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

(2016) Toshio Shimizu et al.   INVESTIGATIONAL NEW DRUGS

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

(2016) Noboru Yamamoto et al.   INVESTIGATIONAL NEW DRUGS

Pembrolizumab (Keytruda)

(2016) Gerry Kwok et al.   Human Vaccines & Immunotherapeutics

Unknown

(2016)   IMMUNOLOGICAL REVIEWS

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab

(2015) Giovanna Scapin et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

14 Mixeno mouse models for in vivo evaluation of anti-human cancer immunotherapeutics

(2014) J. Zhang et al.   EUROPEAN JOURNAL OF CANCER

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Immunogenicity of mAbs in non-human primates during nonclinical safety assessment

(2013) Peter J.K. van Meer et al.   mAbs

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy

(2012) Narendra Chirmule et al.   AAPS Journal

Isotype and glycoform selection for antibody therapeutics

(2012) Roy Jefferis   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

IgG4-related diseases

(2012) Monica Guma et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD

The analysis of the functions of human B and T cells in humanized NOD/shi-scid/γcnull (NOG) mice (hu-HSC NOG mice)

(2009) Yohei Watanabe et al.   INTERNATIONAL IMMUNOLOGY

Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates

(2009) Y. A. Yeung et al.   JOURNAL OF IMMUNOLOGY

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD